Last updated: July 2, 2026
What does United Therapeutics allege in the 1:25-cv-00368 lawsuit against Liquidia?
United Therapeutics Corporation sued Liquidia Technologies, Inc. under the Hatch-Waxman patent dispute framework in a case filed in the U.S. District Court for the District of Maryland, docketed 1:25-cv-00368.
The litigation centers on whether Liquidia’s generic or follow-on product infringes patents asserted by United Therapeutics that cover commercially marketed treprostinil therapies. The case is positioned as an IP challenge tied to an FDA submission for a drug product that is expected to compete with United Therapeutics’ treprostinil franchise.
Which United Therapeutics patents are asserted, and what do they cover?
The case record must specify, for each asserted patent, the claim scope and theory (composition, formulation, method-of-use, or device/administration). No patent numbers, claim mappings, or asserted-infringement counts are provided in the prompt. Without those specifics, a complete infringement and validity analysis cannot be produced.
What is Liquidia’s claimed product pathway in 1:25-cv-00368?
A Hatch-Waxman case’s technical posture typically depends on whether the defendant filed an ANDA or a 505(b)(2) submission, whether it contains a Paragraph IV certification, and the nature of the competing dosage form and release mechanism. The prompt does not include the FDA submission type, Orange Book certifications, the product name, or the accused strength and dosage form.
What is the procedural posture of the case as filed in 2025?
A litigation summary requires at minimum: the complaint filing date, the answer or motion deadlines, whether there is an early TRO/preliminary injunction request, and the schedule set by the court. Those docket particulars are not included in the prompt.
What Orange Book status drives the exclusivity and infringement timing?
For Hatch-Waxman disputes, the timeline analysis depends on:
- the NDA holder(s) and reference listed drug (RLD)
- the Orange Book patent list (drug substance, drug product, and method-of-use patents)
- the expiration dates and any pediatric exclusivity or patent term adjustments
- whether Liquidia challenged specific patents via Paragraph IV
No Orange Book listings, expiration dates, or exclusivity baselines are included in the prompt, so no defensible exclusivity or launch-risk timeline can be generated.
How strong is United Therapeutics’ patent estate in this treprostinil space?
A strength assessment typically quantifies:
- number of active patents by category (composition, formulation, method-of-use)
- remaining term by claim type
- historical litigation outcomes in the class
- likelihood of survived validity defenses (novelty, obviousness, §112)
The prompt contains no asserted patent list, expiration windows, or prior outcomes.
What defenses is Liquidia likely raising in this case?
Standard defenses in Paragraph IV treprostinil litigation include non-infringement (no claim coverage for the accused formulation or method), invalidity (obviousness, lack of written description/enablement), and procedural defenses tied to FDA submission specifics. The prompt provides no claims, no accused features, and no asserted-invalidity arguments.
What relief is United Therapeutics seeking, and what does it signal commercially?
A complete analysis requires the complaint’s requested relief: permanent injunction, temporary restraining relief, attorneys’ fees, and declaratory judgments regarding non-infringement or invalidity. No relief text is included in the prompt.
How does Liquidia’s technology (including formulation delivery approaches) matter to infringement?
Liquidia’s differentiator is often tied to particle engineering and controlled delivery technologies in pulmonary or inhalation-adjacent settings. In infringement analysis, the key questions usually are:
- whether the accused product matches claim limitations on particle size, morphology, or microencapsulation
- whether the release profile or dosing regimen falls within method-of-use claims
- whether the formulation is “substantially similar” to the patented composition claims
The prompt does not state the asserted claim limitations or the accused product design, so infringement-by-feature cannot be executed.
What generic entry risks exist for Liquidia if United Therapeutics wins?
Hatch-Waxman outcomes generally determine:
- whether Liquidia can launch “at risk” before patent expiration
- whether a court-ordered injunction blocks launch until final resolution
- whether settlement triggers a delayed launch date or redesign-around
No injunction posture, settlement posture, or launch timing commitments are present in the prompt.
Timeline: when would exclusivity/patent expiration likely intersect with a Liquidia launch?
A credible timeline requires:
- the earliest relevant patent expiration among asserted patents
- any pediatric exclusivity or regulatory exclusivity extensions
- whether any asserted patents are stayed or in reexamination
- the court schedule for Markman, summary judgment, and trial
Those dates and procedural milestones are not supplied.
Comparative analysis: how does this case compare with other treprostinil patent fights?
Comparisons typically draw on:
- courts handling similar treprostinil formulation and delivery patents
- how judges treat particle/formulation limitations and method-of-use claim specificity
- outcomes in claim construction disputes
The prompt provides no asserted patents or prior case citations to support a specific, data-driven comparison.
Key issues for Markman and claim construction in treprostinil formulation litigation
Claim construction often drives outcomes in formulation and delivery disputes. Common high-impact terms include:
- compositional definitions (ratios, “substantially,” “about,” particle properties)
- functional limitations (effective amount, release kinetics, bioavailability targets)
- method parameters (dosage frequency, administration sequence, patient selection)
No claim terms, no patents, and no Markman briefing data are included in the prompt.
Key Takeaways
- United Therapeutics filed a Hatch-Waxman-style infringement action against Liquidia Technologies in D. Md. (1:25-cv-00368).
- A full patent-by-patent infringement and validity analysis depends on the asserted patent list, Orange Book certifications, and accused product features, none of which are provided in the prompt.
- A defensible assessment of exclusivity timelines, launch risk, and litigation leverage also requires the Orange Book patent expiration data and docket procedural milestones, which are not provided.
FAQs
- Which patents are asserted in United Therapeutics v. Liquidia (1:25-cv-00368)?
- What Paragraph IV certifications does Liquidia make in the underlying FDA submission for the accused treprostinil product?
- What claim types (composition, formulation, method-of-use) are typically at issue in treprostinil patent disputes like this one?
- What remedies can a court order in Hatch-Waxman cases like 1:25-cv-00368, and what triggers launch blocks?
- How do claim construction outcomes (particle/formulation and release functional terms) change infringement probabilities in treprostinil litigation?
References
- U.S. District Court for the District of Maryland, Case No. 1:25-cv-00368 (United Therapeutics Corporation v. Liquidia Technologies, Inc.).
